Keywords: Inflammation, molecular immunology, signal transduction, immune cell metabolism, functional transcriptome and proteomics, neuro-inflammation, asthma, lung inflammation, cancer research
Dr. Chou received her Master in Microbiology of Medical Technology and PhD in Immunology from National Taiwan University. She completed her post-doctoral training in the laboratory of Dr. Jenny Ting at University of North Carolina and has been appointed as Assistant Professor since April 2021.
Dr. Chou has broad interest in the application of cutting-edge ideas and technology to the study of disease-relevant models and mechanisms. Major directions include innate and adaptive immunity, dendritic cell function, autophagy, ER stress, signal transduction, functional proteomics, virus infection, neuro-inflammation, lung inflammation. Clinical issues of interest include multiple sclerosis, asthma, colitis, cancer, infection and inflammation. She has studied the effects of NLRs (nucleotide-binding domain leucine-rich repeat containing) on mice models of these diseases in Dr. Ting’s lab.
Dr. Chou recently published a paper in Nature as first author, showing an unexpected and previously unappreciated role for innate immune receptor AIM2 in Treg cells in adaptive immunity, which is independent of AIM2’s classic function in the innate immunity. She found that AIM2 is important to maintain the normal function of Treg cells, which could not effectively protect mice from developing autoimmune encephalomyelitis and inflammatory colitis without AIM2. Additionally, by using functional proteomics screening, she showed AIM2-RACK1-PP2A-AKT signaling pathway that regulates the metabolism and stability of Treg cells to mitigate autoimmune disease. As a result of these studies, she hopes to modulate the expression or function of molecules in the AIM2 signaling pathway in human Treg cells or effector T cells to eventually affect the outcome of diseases such as cancer or autoimmune disorders in the future.
Wei-Chun Chou in UNC Genetics News
April 10, 2023
Department of Genetics Publications for March 26th – April 8th, 2023
Department of Genetics faculty, postdocs, students and collaborators published 10 papers during March 26th – April 8th, 2023.
October 10, 2022
Department of Genetics Publications for September 25th – October 8th, 2022
Department of Genetics faculty, postdocs, students and collaborators published 10 papers during September 25th – October 8th, 2022.
August 16, 2022
Department of Genetics Publications for July 31st – August 13th, 2022
Department of Genetics faculty, postdocs, students and collaborators published 7 papers during July 31st – August 13th, 2022. A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids. Ramdas S, Judd J, Graham SE, Kanoni S, Wang Y, Surakka I, Wenz B, Clarke SL, Chesi A, Wells A, Bhatti KF, Vedantam S, …
November 1, 2021
Department of Genetics Publications October 17th – 30th, 2021
Department of Genetics faculty, postdocs, students and collaborators published 14 papers during October 17th – 30th 2021.
June 4, 2021
Department of Genetics Welcomes New Faculty
Four new Assistant Professors have recently been appointed in the Department of Genetics.
February 8, 2021
Department of Genetics Publications for Jan. 24 – Feb. 6, 2021
Department of Genetics faculty, postdocs, students and collaborators published twenty papers during Jan. 24 – Feb. 6, 2021.
January 28, 2021
Scientists Find Key Function of Molecule in Cells Crucial for Regulating Immunity
UNC School of Medicine and UNC Lineberger scientists co-led by Jenny Ting, PhD, and Yisong Wan, PhD, uncovered a new molecular pathway important for the regulation of the adaptive immune system and the mitigation of autoimmune disease.
November 2, 2020
Department of Genetics Publications for October 11-31, 2020
Department of Genetics faculty, postdocs, students and collaborators published 18 papers during October 11-31, 2020. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, …